NL-OMON44787已完成2 期
A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER - GO29293
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 13
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Histologically or cytologically documented locally advanced (T4b, any N; or any T, N 2*3) or metastatic (M1, Stage IV) TCC (also termed urothelial cell carcinoma) of the urothelium (including renal pelvis, ureters, urinary bladder, urethra)
- •Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks (blocks preferred) or at least 15 unstained slides, with an associated pathology report, for central testing and determined to have sufficient viable tumor content prior to study enrollment; tumor specimens will be evaluated for PD-L1 expression; patients with fewer than 15 unstained slides available at baseline (but no fewer than 10) may be eligible following discussion with Medical Monitor.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Patients with ECOG 2 are allowed in Cohort 1.
- •Measurable disease, as defined by RECIST v1.1 Previously irradiated lesions should not be counted as target lesions.;Cohort 1-Specific Inclusion Criteria
- •No prior chemotherapy for inoperable locally advanced or metastatic or recurrent UBC
- •Ineligible (*unfit*) for cisplatin-based chemotherapy as defined by any one of the following criteria:
- •- Impaired renal function (glomerular filtration rate [GFR] > 30 but < 60 mL/min). GFR should be assessed by direct measurement (i.e., creatinine clearance or ethyldediaminetetra-acetate) or, if not available, by calculation from serum/plasma creatinine (Cockcroft-Gault formula)
- •- A hearing loss (measured by audiometry) of 25 dB at two contiguous frequencies
- •- Grade 2 or greater peripheral neuropathy (i.e., sensory alteration or parasthesis including tingling)
- •- ECOG performance score of 2;Cohort 2-Specific Inclusion Criteria
- •Disease progression during or following treatment with at least one platinum-containing regimen (e.g., gemcitabine and cisplatin [GC], methotrexate, vinblastine, doxorubicin, and cisplatin [MVAC], CarboGem, etc.) for inoperable locally advanced or metastatic urothelial carcinoma or disease recurrence
排除标准
- •Cancer Specific Exclusion Criteria
- •Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment
- •Active or untreated central nervous system (CNS) metastases as determined by CT or MRI evaluation during screening and prior radiographic assessments
- •Leptomeningeal disease;Medication-Related Exclusion Criteria:
- •Prior treatment with CD137 agonists or immune checkpoint blockade therapies,
- •Treatment with systemic immunostimulatory agents within 6 weeks or five half-lives of the drug, whichever is shorter, prior to Cycle 1, Day 1
- •Treatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to Cycle 1, Day 1, or anticipated requirement for systemic immunosuppressive medications during the trial
研究者
相似试验
已完成
2 期
A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF ATEZOLIZUMAB IN PATIENTS WITH PD L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCERNL-OMON45051Roche Nederland B.V.13
进行中（未招募）
1 期
Clinical study to evaluate atezolizumab (MPDL3280A) in patients with PD-L1- positive locally or metastatic non-small cell lung cancerEUCTR2013-000177-69-BEGenentech, Inc.130
进行中（未招募）
1 期
Clinical study to evaluate atezolizumab (MPDL3280A) in patients with PD-L1- positive locally or metastatic non-small cell lung cancerPD-L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCERMedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000177-69-GBGenentech, Inc.137
进行中（未招募）
1 期
A Kadcyla (also known as trastuzumab emtansine or T-DM1) study in patients with HER2-positive lung cancer after chemotherapy treatmentEUCTR2014-001237-83-PLF. Hoffmann-La Roche Ltd40
进行中（未招募）
1 期
A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF TRASTUZUMAB EMTANSINE IN PATIENTS WITH HER2 IHC-POSITIVE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE RECEIVED AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEEUCTR2014-001237-83-ITF. Hoffmann-La Roche Ltd49